Search results for "inadequate responders"

showing 1 items of 1 documents

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: Efficacy following prior methylphenidate trea…

2016

Guanfacine extended release (GXR) and atomoxetine (ATX) are nonstimulant treatments for attention-deficit/hyperactivity disorder (ADHD). As nonstimulant treatments are often used after stimulants in ADHD, GXR was assessed relative to prior stimulant treatment in a randomized controlled trial (RCT), in which ATX was included as a reference arm, and in the open-label phase of a randomized-withdrawal study (RWS). Participants were 6–17 years old with ADHD Rating Scale version IV (ADHD-RS-IV) scores ≥32 and Clinical Global Impressions – Severity scores ≥4. RCT participants received dose-optimized GXR (1–7 mg/day), ATX (10–100 mg/day), or placebo for 10–13 weeks. RWS participants received dose-o…

medicine.medical_specialtyNeuropsychiatric Disease and Treatmentmedicine.medical_treatmenteffectivenessmethylphenidateNeurosciences. Biological psychiatry. NeuropsychiatryPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialRating scalelawInternal medicinemental disordersmedicineAttention deficit hyperactivity disorderADHD0501 psychology and cognitive sciencesPsychiatryRC346-429child and adolescentguanfacineOriginal Researchbusiness.industryMethylphenidate05 social sciencesAtomoxetinetrialmedicine.disease030227 psychiatryGuanfacineinadequate respondersStimulantNeurology. Diseases of the nervous systembusinessGXRatomoxetine050104 developmental & child psychologymedicine.drugRC321-571
researchProduct